Creo upbeat on first-in-human clinical use of 'MicroBlate Fine'

The AIM-traded firm said the device was used to successfully ablate pancreatic tumour tissue under endoscopic ultrasound guidance, without any procedural complications.

It said the MicroBlate Fine device has the same dimensions as a routine biopsy needle, “greatly reducing” the risk of procedural bleeding and allowing “very accurate” targeting of microwave ablation in highly perfused organs such as the liver, kidney, lung as well as the pancreas.

“We are very pleased with the first in-man clinical use of the MicroBlate Fine device, bringing fine needle microwave ablation into clinical practice for the first time and in particular, as in this case, in the hands of GI physicians,” said chief executive officer Craig Gulliford.

“This is a fantastic milestone for the company and the entire Creo team.

“We look forward to further clinical firsts and regulatory announcements related to our increasing suite of GI devices.”

At 1146 GMT, shares in Creo Medical Group were up 21.37% at 208.08p.